Precision Medicine

The FDA has approved Pylarify TruVu (piflufolastat F 18), a new PET imaging agent that helps detect prostate cancer that has spread or returned. Pylarify TruVu targets the Prostate-Specific Membrane Antigen (PSMA) on cancer cells, making them visible on a PET/CT scan. The approval covers two groups of men: those with high-risk prostate cancer before […]

A new study shows that circulating tumor DNA (ctDNA) can predict the effectiveness of immunotherapy in advanced Melanoma just 3–4 weeks after treatment starts—much faster than standard scans. Using the tumor-informed Signatera assay, doctors can track tumor DNA fragments in the blood to monitor response in real time. Early changes in ctDNA were strongly linked

New data from the NeoPembrOV/GINECO trial show that in high-grade serous ovarian cancer, testing PD-L1 levels in metastatic tumors predicts response to immunotherapy better than testing the primary tumor. Patients with high PD-L1 in metastatic sites had a 54% lower risk of disease progression when treated with pembrolizumab plus chemotherapy, while primary tumor PD-L1 was

Treatment for metastatic pancreatic cancer is becoming more personalized, focusing on controlling aggressive disease while considering each patient’s quality of life. Doctors now tailor therapy based on a patient’s ability to tolerate side effects and their tumor’s specific biomarkers, rather than just survival statistics. The FDA-approved NALIRIFOX (2024) adds a new first-line option alongside FOLFIRINOX

Researches have presented a new treatment strategy for pancreatic ductal adenocarcinoma (PDAC), a highly aggressive cancer with a survival rate of about 13%. While most PDAC cases have KRAS mutations, around 22% also lose the MTAP gene. This MTAP deletion causes a buildup of a molecule called MTA, creating a unique weakness in cancer cells. Researchers developed a

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with rising cases and strong resistance to standard chemotherapy. Precision oncology is bringing new hope by identifying biomarkers and targeted treatments that can guide personalized care. Chemotherapy, including FOLFIRINOX and gemcitabine plus nab-paclitaxel, remains the main treatment, but response rates rarely exceed 40% because of

A new, highly targeted gene therapy developed by UC Davis scientists, shows promise for treating cancers caused by the Kaposi’s sarcoma-associated herpesvirus (KSHV), such as Kaposi’s sarcoma. The preclinical study, published in Molecular Therapy Oncology, utilizes a harmless adeno-associated virus (AAV) to deliver a “Trojan horse” gene into KSHV-infected cancer cells. This therapy is activated

CLDN18.2, a stomach-specific tight junction protein, is normally low but becomes upregulated in multiple cancers, including gastric, pancreatic, colorectal, breast, and liver tumors. This dysregulation promotes tumor growth and spread, making it a promising biomarker and therapeutic target. Its expression is regulated by transcriptional, epigenetic, and signaling pathways, and it has context-dependent effects—mostly oncogenic, but

Precision medicine is transforming kidney cancer treatment by tailoring therapies to each patient’s tumor genetics and molecular profile. Genetic and molecular profiling identifies mutations and pathways driving tumor growth, guiding targeted drugs like the HIF-2α inhibitor belzutifan. Personalized cancer vaccines are emerging, using tumor-specific neoantigens to train the immune system, with early trials showing some patients

ITargeted therapies are transforming brain tumor treatment by focusing on specific genetic mutations rather than broadly attacking all dividing cells. This improves precision and reduces side effects. A key example is Vorasidenib, approved for gliomas with IDH1 or IDH2 mutations, which can delay tumor progression. Researchers are also developing agents like MT-125 that disrupt cancer